Critical evaluation of artificial intelligence as a digital twin of pathologists for prostate cancer pathology.

Journal: Scientific reports
Published Date:

Abstract

Prostate cancer pathology plays a crucial role in clinical management but is time-consuming. Artificial intelligence (AI) shows promise in detecting prostate cancer and grading patterns. We tested an AI-based digital twin of a pathologist, vPatho, on 2603 histological images of prostate tissue stained with hematoxylin and eosin. We analyzed various factors influencing tumor grade discordance between the vPatho system and six human pathologists. Our results demonstrated that vPatho achieved comparable performance in prostate cancer detection and tumor volume estimation, as reported in the literature. The concordance levels between vPatho and human pathologists were examined. Notably, moderate to substantial agreement was observed in identifying complementary histological features such as ductal, cribriform, nerve, blood vessel, and lymphocyte infiltration. However, concordance in tumor grading decreased when applied to prostatectomy specimens (κ = 0.44) compared to biopsy cores (κ = 0.70). Adjusting the decision threshold for the secondary Gleason pattern from 5 to 10% improved the concordance level between pathologists and vPatho for tumor grading on prostatectomy specimens (κ from 0.44 to 0.64). Potential causes of grade discordance included the vertical extent of tumors toward the prostate boundary and the proportions of slides with prostate cancer. Gleason pattern 4 was particularly associated with this population. Notably, the grade according to vPatho was not specific to any of the six pathologists involved in routine clinical grading. In conclusion, our study highlights the potential utility of AI in developing a digital twin for a pathologist. This approach can help uncover limitations in AI adoption and the practical application of the current grading system for prostate cancer pathology.

Authors

  • Okyaz Eminaga
    Okyaz Eminaga, Stanford Medical School, Stanford, CA; University Hospital of Cologne, Cologne, France; Nurettin Eminaga, St Mauritius Therapy Clinic, Meerbusch; Axel Semjonow, University Hospital Muenster; and Bernhard Breil, Niederrhein University of Applied Sciences, Krefeld, Germany.
  • Mahmoud Abbas
    Department of Pathology, University of Muenster, Muenster, Germany. Electronic address: mahabbas74@googlemail.com.
  • Christian Kunder
    Department of Pathology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
  • Yuri Tolkach
    Institute of Pathology, University Hospital Cologne, Cologne, Germany. yuri.tolkach@gmail.com.
  • Ryan Han
    Department of Computer Science, Stanford University, Stanford, USA.
  • James D Brooks
    Department of Urology, Stanford School of Medicine, CA.
  • Rosalie Nolley
    Department of Urology, Stanford University School of Medicine, Stanford, CA, USA.
  • Axel Semjonow
    Okyaz Eminaga, Stanford Medical School, Stanford, CA; University Hospital of Cologne, Cologne, France; Nurettin Eminaga, St Mauritius Therapy Clinic, Meerbusch; Axel Semjonow, University Hospital Muenster; and Bernhard Breil, Niederrhein University of Applied Sciences, Krefeld, Germany.
  • Martin Boegemann
    University Hospital Muenster, Germany.
  • Robert West
    Research Department of Behavioural Science and Health, University College London, London, England, UK.
  • Jin Long
    Center for Artificial Intelligence in Medicine and Imaging, Stanford University, 1701 Page Mill Road, Palo Alto, CA, 94304, USA.
  • Richard E Fan
    Department of Urology, Stanford University, Stanford, CA 94305, USA.
  • Olaf Bettendorf
    Institute for Pathology and Cytology, Schuettorf, Germany. O_Bettendorf@web.de.